

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



邁博藥業
Mabpharm Limited
迈博药业有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2181)

DATE OF BOARD MEETING

The board of directors (the “**Board**”) of Mabpharm Limited (the “**Company**”) hereby announces that a meeting of the Board will be held on Wednesday, August 28, 2024 for the purpose of, among other matters, considering and approving the interim results of the Company and its subsidiaries for the six months ended June 30, 2024 and its publication and transacting any other business.

By order of the Board
Mabpharm Limited
Jiao Shuge
Chairman

Hong Kong, August 15, 2024

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Wang Hao, Mr. Li Yunfeng, Mr. Tao Jing, Dr. Hou Sheng and Dr. Qian Weizhu as executive Directors; Mr. Jiao Shuge and Mr. Cen Jialin as non-executive Directors; and Mr. Guo Liangzhong, Dr. Zhang Yanyun, Mr. Leung, Louis Ho Ming and Dr. Tao Qian as independent non-executive Directors.